The solution flags cases of pulmonary embolism in chest CTs to prioritize patients at high risk.
Aidoc, an artificial intelligence (AI) solutions provider for radiologists, announced today that the U.S. Food and Drug Administration (FDA) granted it clearance for its pulmonary embolism solution.
The platform helps radiologists flag cases of pulmonary embolism in chest CTs.
Aidoc’s solutions analyze medical images after the patient is scanned and notifies the radiologist of cases with suspected findings. This helps the radiologist prioritize time-sensitive and potentially life-threatening cases.
The company claims that its solutions cut the time from scan to diagnosis from hours to under five minutes, which speeds up treatment and improves prognosis.
“We strive to provide our customers with comprehensive end-to-end solutions and have put a lot of effort in developing a scalable AI platform,” said Elad Walach, co-founder and CEO of Aidoc.
Up to 200,000 people in the U.S. die from pulmonary embolisms each year. And undetected or late-detected pulmonary embolisms are some of the most common causes of preventable death in hospitalized patients.
AI is already a proven tool in identifying suspected pulmonary embolism.
A research team found that by combining an algorithm with the D-dimer blood test, they prevented the need for CT scans in 39% of patients with suspected pulmonary embolism.
The approval comes weeks after Aidoc raised $27 million in funding to grow its software suite.
Get the best insights in digital health directly to your inbox.
How AI Is Shaking Up Healthcare, Beyond Diagnostics
AI Algorithm Predicts Risk of FH with High Accuracy
The ACR Launches AI-Lab to Empower Radiologists to Learn About AI